Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00262236
- Lead Sponsor
- Novartis
- Brief Summary
This is a study for people diagnosed with hypertension to compare the safety and effectiveness of aliskiren alone and in combination with atenolol. Each patient will be in the study for 12 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 693
Inclusion Criteria
- Outpatients 18 years of age and older.
- Patients with essential hypertension.
Exclusion Criteria
Severe hypertension, Current diagnosis of heart failure, History or evidence of a secondary form of hypertension, Participation in any investigational drug study within one month of planned participation,
Other protocol-defined inclusion/exclusion criteria may apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from baseline in diastolic blood pressure after 12 weeks
- Secondary Outcome Measures
Name Time Method Diastolic blood pressure < 90 mmHg or a reduction of > 10 mmHg after 12 weeks Blood pressure of < 140/90 mmHg after 12 weeks Change from baseline in systolic blood pressure after 12 weeks
Trial Locations
- Locations (1)
Novartis
🇨🇭Basel, Switzerland